Day 3

DESTINY TRIAL: Stent de hastes finas com polímero eluidor de sirolimus

solaci
solaci
469
0

7_pedro_lemos

Pedro Lemos
2014-09-16

Previous article
OPTIMIZE: 3 months versus 12 months of dual anti-aggregation with zotarolimus-eluting stents
Next article
I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform
solaci
solaci

More articles by this author

OPTIMIZE: 3 months versus 12 months of dual anti-aggregation with zotarolimus-eluting stents

solaci - 0
The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific types of stents is unclear. This study...

SECURITY: 6 months versus 12 months of dual anti-aggregation using 2nd generation DES

solaci - 0
This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus 1 year (n = 717) dual anti-aggregation...

VELOCITY: Peritoneal hypothermia in patients undergoing primary angioplasty

solaci - 0
There are clinics hypothesis that systemic hypothermia (≤34.9) could reduce infarct size if set before reperfusion. Peritoneal lavage had a well-established safety profile and...

TRANSLATE-ACS: One-year prasugrel versus clopidogrel after acute coronary syndrome

solaci - 0
Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute coronary syndrome, especially if the patient has...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 3

OPTIMIZE: 3 months versus 12 months of dual anti-aggregation with zotarolimus-eluting stents

The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific types of stents...
solaci -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Dr. Omar Tupayachi - 0
Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Dr. Juan Manuel Pérez - 0
Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Dr. Juan Manuel Pérez - 0
Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...